Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Falk Russell A"'
Autor:
Kevin L. Russell, Richard E. Rupp, Javier O. Morales-Ramirez, Clemente Diaz-Perez, Charles P. Andrews, Andrew W. Lee, Tyler S. Finn, Kara S. Cox, Amy Falk Russell, Margaret M. Schaller, Jason C. Martin, Donna M. Hyatt, Sabrina Gozlan-Kelner, Androniki Bili, Beth-Ann G. Coller
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 18, Iss 5 (2022)
Dengue (DENV) is a mosquito-borne virus with four serotypes causing substantial morbidity in tropical and subtropical areas worldwide. V181 is an investigational, live, attenuated, quadrivalent dengue vaccine. In this phase 1 double-blind, placebo-co
Externí odkaz:
https://doaj.org/article/48a11da47b0347aeb48e341a669a7e87
Autor:
Susan B. Manoff, Michele Sausser, Amy Falk Russell, Jason Martin, David Radley, Donna Hyatt, Christine C. Roberts, Jason Lickliter, Janakan Krishnarajah, Andrew Bett, Sheri Dubey, Tyler Finn, Beth-Ann Coller
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 15, Iss 9, Pp 2195-2204 (2019)
There is an unmet medical need for vaccines to prevent dengue. V180 is an investigational recombinant subunit vaccine that consists of truncated dengue envelope proteins (DEN-80E) for all 4 serotypes. Three dosage levels of the tetravalent DEN-80E an
Externí odkaz:
https://doaj.org/article/e4be8a3f1f7443309a7d49c43205d80c
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Kevin Russell, Richard E Rupp, Javier O Morales-Ramirez, Clemente Diaz-Perez, Charles P Andrews, Andrew W Lee, Tyler S Finn, Kara Cox, Amy Falk Russell, Margaret M Schaller, Jason C Martin, Donna M Hyatt, Sabrina Gozlan-Kelner, Androniki Bili, Beth-Ann Coller
Publikováno v:
Open Forum Infectious Diseases
Background Dengue (DENV) is a mosquito-borne virus with four serotypes causing substantial morbidity in tropical and subtropical areas worldwide. A dengue vaccine that can be given to both seronegative and seropositive populations remains an importan
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4e13e3127c0ae478179c07c64404ca5e
http://europepmc.org/articles/PMC8643940
http://europepmc.org/articles/PMC8643940
Autor:
Beth D. Kirkpatrick, Melissa Cook, Michele Sausser, Beulah P. Sabundayo, Liman Wang, Stephen S. Whitehead, Helen He, Anna P. Durbin, Donna Hyatt, Kristen K. Pierce, Jeffrey R. Sachs, Beth Ann Coller, Amy Falk Russell, Andrew W. Lee, Jason C. Martin, Palmtama L. Grier
Publikováno v:
Am J Trop Med Hyg
New dengue vaccines are needed to prevent this globally expanding vector-borne disease. The V180 vaccine candidate consists of four recombinant, soluble, dengue virus envelope glycoproteins and has been previously evaluated in two clinical trials for
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8dcf30a2da4a667888787fe2e2afeb6e
https://pubmed.ncbi.nlm.nih.gov/32394880
https://pubmed.ncbi.nlm.nih.gov/32394880
Autor:
Christine C. Roberts, Beth-Ann Coller, Michele Sausser, David Radley, Amy Falk Russell, Jason C. Martin, Janakan Krishnarajah, Susan B. Manoff, Donna Hyatt, Sheri Dubey, Andrew J. Bett, Tyler S. Finn, Jason Lickliter
Publikováno v:
Hum Vaccin Immunother
There is an unmet medical need for vaccines to prevent dengue. V180 is an investigational recombinant subunit vaccine that consists of truncated dengue envelope proteins (DEN-80E) for all 4 serotypes. Three dosage levels of the tetravalent DEN-80E an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a1761eb2177b5d055cc040d32ea0db28
https://pubmed.ncbi.nlm.nih.gov/30427741
https://pubmed.ncbi.nlm.nih.gov/30427741
Autor:
Bernard J.C. Macatangay, Robbie B. Mailliard, Paula W. Annunziato, Cheryl Jennings, Marshall J. Glesby, Dawn R Bozzolo, Sarah W. Read, Charles R. Rinaldo, Janet Andersen, Lynette Purdue, Jason C. Martin, Amy Falk Russell, Zoran Popmihajlov, Constance A. Benson, Michael C. Keefer, Pablo Tebas, Jeffrey L. Lennox
BACKGROUND: Herpes zoster (HZ) risk is increased in human immunodeficiency virus (HIV)–infected persons. Live attenuated zoster vaccine (ZV) reduces HZ incidence and severity in adults; safety and immunogenicity data in HIV-infected adults are limi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dfdf7f6fe1e24665ed807cbda51d5c7f
https://europepmc.org/articles/PMC6233680/
https://europepmc.org/articles/PMC6233680/
Autor:
Katia Schlienger, Jin Xu, Chester L. Fisher, Wolfgang Spieler, Janie Parrino, Jon E. Stek, Xiaoming Li, Shu-Chih Su, Kathleen E. Coll, Jeffrey L. Silber, Amy Falk Russell
Publikováno v:
Vaccine. 33:3129-3134
Background This randomized, placebo-controlled study assessed the safety, tolerability, and immunogenicity of live virus zoster vaccine (ZV) in individuals receiving chronic/maintenance systemic corticosteroid therapy (daily dose equivalent of 5–20
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9df11f9fc27410730ba940434f172c0f
https://doi.org/10.1016/j.vaccine.2015.04.090
https://doi.org/10.1016/j.vaccine.2015.04.090
Autor:
Manoff, Susan B., Sausser, Michele, Falk Russell, Amy, Martin, Jason, Radley, David, Hyatt, Donna, Roberts, Christine C., Lickliter, Jason, Krishnarajah, Janakan, Bett, Andrew, Dubey, Sheri, Finn, Tyler, Coller, Beth-Ann
Publikováno v:
Human Vaccines & Immunotherapeutics; 2019, Vol. 15 Issue 9, p2195-2204, 10p
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.